Roivant Sciences (NASDAQ:ROIV) Insider Sells $27,492,361.50 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 1,012,610 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $27.15, for a total value of $27,492,361.50. Following the completion of the sale, the insider directly owned 13,736,547 shares in the company, valued at $372,947,251.05. This represents a 6.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Frank Torti also recently made the following trade(s):

• On Thursday, February 19th, Frank Torti sold 1,400,000 shares of Roivant Sciences stock. The stock was sold at an average price of $27.42, for a total transaction of $38,388,000.00.
• On Monday, February 23rd, Frank Torti sold 587,390 shares of Roivant Sciences stock. The stock was sold at an average price of $27.51, for a total transaction of $16,159,098.90.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock traded up $0.61 on Monday, hitting $27.76. The company had a trading volume of 4,414,766 shares, compared to its average volume of 6,823,292. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $27.94. The company has a market cap of $19.87 billion, a PE ratio of -23.73 and a beta of 1.22. The business has a 50-day simple moving average of $23.44 and a 200-day simple moving average of $19.07.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Leerink Partners boosted their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, December 15th. HC Wainwright lifted their price target on Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Guggenheim increased their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $30.00 target price on shares of Roivant Sciences in a research note on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $28.69.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors have recently modified their holdings of ROIV. Morgan Stanley increased its holdings in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares in the last quarter. Vanguard Group Inc. raised its position in Roivant Sciences by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP raised its position in Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after buying an additional 2,603,260 shares during the last quarter. State Street Corp lifted its stake in Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after acquiring an additional 911,827 shares in the last quarter. Finally, UBS Group AG boosted its position in Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after acquiring an additional 15,645,836 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.